These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30534926)

  • 21. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis - Beijing, China, 2014-2016.
    Zhao D; Ma R; Zhou T; Yang F; Wu J; Sun H; Liu F; Lu L; Li X; Zuo S; Yao W; Yin J
    MMWR Morb Mortal Wkly Rep; 2017 Dec; 66(49):1357-1361. PubMed ID: 29240729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Introduction of sequential inactivated polio vaccine-oral polio vaccine schedule for routine infant immunization in Brazil's National Immunization Program.
    Domingues CM; de Fátima Pereira S; Cunha Marreiros AC; Menezes N; Flannery B
    J Infect Dis; 2014 Nov; 210 Suppl 1(0 1):S143-51. PubMed ID: 25316829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.
    Jaiswal N; Singh S; Agarwal A; Chauhan A; Thumburu KK; Kaur H; Singh M
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011780. PubMed ID: 31858595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. India's Preparedness for Introduction of IPV and Switch from tOPV to bOPV.
    Haldar P; Agrawal P
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S44-S49. PubMed ID: 27771639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States.
    Marin M; Patel M; Oberste S; Pallansch MA
    MMWR Morb Mortal Wkly Rep; 2017 Jan; 66(1):23-25. PubMed ID: 28081056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polio endgame: the global switch from tOPV to bOPV.
    Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M
    Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Introduction of inactivated poliovirus vaccine into oral poliovirus vaccine-using countries.
    Wkly Epidemiol Rec; 2003 Jul; 78(28):241-50. PubMed ID: 15571166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surveillance for poliovirus vaccine adverse events, 1991 to 1998: impact of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine.
    Wattigney WA; Mootrey GT; Braun MM; Chen RT
    Pediatrics; 2001 May; 107(5):E83. PubMed ID: 11331733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.
    Menning L; Garg G; Pokharel D; Thrush E; Farrell M; Kodio FK; Veira CL; Wanyoike S; Malik S; Patel M; Rosenbauer O
    J Infect Dis; 2017 Jul; 216(suppl_1):S24-S32. PubMed ID: 28838189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.
    Duintjer Tebbens RJ; Thompson KM
    J Infect Dis; 2014 Nov; 210 Suppl 1():S485-97. PubMed ID: 25316871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region.
    Fahmy K; Hampton LM; Langar H; Patel M; Mir T; Soloman C; Hasman A; Yusuf N; Teleb N
    J Infect Dis; 2017 Jul; 216(suppl_1):S86-S93. PubMed ID: 28838199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Polio vaccines, eradication and posterradication].
    Salmerón García F; Portela Moreira A; Soler Soneira M; López Hernández S; Chamorro Somoza Díaz-Sarmiento M; Pérez González I; Rubio Gómez MI; Pérez González A; Sagredo Rodríguez A; Ruiz Antúnez S; Timón Jiménez M; Frutos Cabanillas G
    Rev Esp Salud Publica; 2013; 87(5):497-505. PubMed ID: 24322286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group.
    Modlin JF; Halsey NA; Thoms ML; Meschievitz CK; Patriarca PA
    J Infect Dis; 1997 Feb; 175 Suppl 1():S228-34. PubMed ID: 9203721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial.
    He H; Wang Y; Deng X; Yue C; Tang X; Li Y; Liu Y; Yin Z; Zhang G; Chen Z; Xie S; Wen N; An Z; Chen Z; Wang H
    Lancet Infect Dis; 2020 Sep; 20(9):1071-1079. PubMed ID: 32442523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
    Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
    Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coverage estimates and patterns of inactivated poliovirus vaccine (IPV) use prior to and during the polio eradication endgame, Jinan City, China, 2010-2015.
    Chang C; Zhang J; Zhou J; Cao R; Song K; Liu C; Zhang X; Geng X; Liu X; Li C
    Hum Vaccin Immunother; 2016 Nov; 12(11):2749-2752. PubMed ID: 27437792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
    Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
    J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.